The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.
 
Suwicha Limvorasak
Research Funding - Pfizer
 
Kyung Kim
No Relationships to Disclose
 
Crystal Leung Dobbs
No Relationships to Disclose
 
Edwin Melencio Posadas
Consulting or Advisory Role - Bayer; CytoLumina; Myovant Sciences
Speakers' Bureau - Bayer
Research Funding - PFizer
Patents, Royalties, Other Intellectual Property - Patent on NanoVelcro Assay for CTCs in prostate cancer
 
Kevin Scher
No Relationships to Disclose
 
Johnny Chang
No Relationships to Disclose
 
Vi Kien Chiu
Research Funding - Alkermes (Inst); Arcus Biosciences (Inst); BioNTech SE (Inst); Incyte (Inst); Intra-Immusg (Inst); Leap Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Seattle Genetics/Astellas (Inst); TyrNovo (Inst)
 
Marcio A. Diniz
No Relationships to Disclose
 
Andre Rogatko
No Relationships to Disclose
 
Hilary Teaford
No Relationships to Disclose
 
Leanne Sakamoto
No Relationships to Disclose
 
Bruce Vinson
No Relationships to Disclose
 
Vipul Patel
No Relationships to Disclose
 
Robert A. Figlin
Leadership - 4Dx; Apollomics
Stock and Other Ownership Interests - 4Dx
Consulting or Advisory Role - Johnson & Johnson
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Merck (Inst); Peloton Therapeutics (Inst)
 
Rita Shane
No Relationships to Disclose
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck KGaA; Mirati Therapeutics; Seagen; Takeda
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)